Clinical trials: Recurrent Acute Rhinosinusitis
Chronic Rhinosinusitis, Recurrent Acute Rhinosinusitis
Global Sinus Surgery Registry
This study evaluates long-term safety and effectiveness of primary sinus surgery in a real-world population of adults with chronic rhinosinusitis (CRS) or recurrent acute rhinosinusitis (RARS).
- Trial name
- OASIS (NCT02347943)
- Where
- 25 sites in United States
- Volunteers
- 252 people
- Sponsor
- Integra LifeSciences Corporation
Recurrent Acute Rhinosinusitis
Evaluation of Nitric Oxide Nasal Spray (NONS) for Treatment of Recurrent Acute Rhinosinusitis
A two-week therapy of nitric oxide nasal spray (NONS) vs Placebo (saline nasal spray) initiated immediately after the onset of a new Recurrent Acute Rhinosinusitis (RARS) episode to assess the acceleration to clinical success…
- Trial name
- NONS-RARS-01 (NCT06264141)
- Testing
- Nitric Oxide Releasing Solution, Nasal spray with isotonic saline
- Where
- 7 sites in Canada
- Volunteers
- 162 people
- Sponsor
- Sanotize Research and Development corp.
Acute Rhinosinusitis, Recurrent Acute Rhinosinusitis
NAC Inhalation in the Treatment Of Symptomatic acuTe rhinosinUSitis
N-acetylcysteine (NAC), known to have mucolytic and antioxidant effects, is widely used to treat respiratory diseases and manage post-surgery pulmonary complications.
- Conditions
- Acute Rhinosinusitis, Recurrent Acute Rhinosinusitis, Chronic Rhinosinusitis
- Trial name
- NOTUS (NCT04131686)
- Where
- South Korea
- Volunteers
- 294 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Recurrent Acute Rhinosinusitis
Comparison of Balloon Sinuplasty In-Office Versus Medical Management for Recurrent Acute Sinusitis Patients (CABERNET)
This post-market study aims to compare health outcomes for Recurrent Acute Rhinosinusitis (RARS) patients treated with balloon sinus dilation (BSD) versus medical management alone.
- Trial name
- CABERNET (NCT01714687)
- Testing
- balloon sinus dilation, medical therapy
- Where
- 5 sites in United States
- Volunteers
- 59 people
- Sponsor
- Integra LifeSciences Corporation
Recurrent Upper-Respiratory Tract Infections
CLEARI (Clinical Efficacy Assessment on Recurrent Upper-Respiratory Tract Infections) Study
The purpose of this study is to assess the efficacy and safety of J022X ST for prevention of Recurrent Upper-Respiratory Tract Infections (RURTI) compared to placebo in children of younger age who develop infectious diseases more…
- Trial name
- NCT01948856
- Testing
- J022X ST
- Where
- 24 sites in Italy, Lithuania and 3 more
- Volunteers
- 1,003 people
- Sponsor
- Pierre Fabre Medicament